{
    "clinical_study": {
        "@rank": "147802", 
        "arm_group": [
            {
                "arm_group_label": "Fluticasone/salmeterol high dose", 
                "arm_group_type": "Experimental", 
                "description": "COPD patients treating with high dose of ICS (Fluticasone 1000ug/day) combined with Salmeterol (25ug/day)"
            }, 
            {
                "arm_group_label": "Fluticasone/Salmeterol medium dose", 
                "arm_group_type": "Active Comparator", 
                "description": "COPD patients treating with medium dose of ICS (Fluticasone 500ug/day) combined with Salmeterol (25ug/day)"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to investigate and compare treatment efficacy with high and medium dose of\n      fluticasone in combination with salmeterol in COPD patients."
        }, 
        "brief_title": "Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Percentage of Annual Acute Exacerbation", 
            "Quality of Life"
        ], 
        "detailed_description": {
            "textblock": "Diagnosis and criteria for inclusion and exclusion:\n\n      Inclusion:\n\n        1. Male or female outpatients aged 40 years\u2267\n\n        2. Current or ex-smoker, with smoking history 10 pack\u2267- years\n\n        3. COPD (FEV1/FVC < 70%) patients with post-bronchodilator FEV1 70% \u2266predicted value,\n           without bronchial reversibility (10% increase post \u2266bronchodilator)\n\n      Exclusion:\n\n        1. Diagnosis or suspicion of sleep apnea.\n\n        2. Concurrent rhinitis, eczema, and asthma.\n\n        3. Clinically overt bronchiectasis, lung cancer, active tuberculosis, or other known\n           specific pulmonary disease.\n\n        4. A chest X-ray indicating diagnosis other than COPD that might interfere with the study.\n\n        5. Major disease abnormalities are uncontrolled on therapy.\n\n        6. Alcohol or medication abuse.\n\n        7. Patients had lower respiratory tract infections or received systemic steroid in the 4\n           weeks prior to the commencement of study.\n\n        8. Unable or unwilling to comply with all protocol\n\n      Test product:\n\n      fluticasone125 mcg/salmetrol 25 mcg ( Seretide 125 Evohaler ) fluticasone250 mcg/salmetrol\n      25 mcg ( Seretide 250 Evohaler ) Formulation: fluticasone/salmeterol, 125/25 mcg/puff Dose:\n      2 puffs bid"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or female outpatients aged 40 years\u2267\n\n          2. Current or ex-smoker, with smoking history 10 pack\u2267- years\n\n          3. COPD (FEV1/FVC < 70%) patients with post-bronchodilator FEV1 70% \u2266predicted value,\n             without bronchial reversibility (10% increase post \u2266bronchodilator)\n\n        Exclusion Criteria:\n\n          1. Diagnosis or suspicion of sleep apnea.\n\n          2. Concurrent rhinitis, eczema, and asthma.\n\n          3. Clinically overt bronchiectasis, lung cancer, active tuberculosis, or other known\n             specific pulmonary disease.\n\n          4. A chest X-ray indicating diagnosis other than COPD that might interfere with the\n             study.\n\n          5. Major disease abnormalities are uncontrolled on therapy.\n\n          6. Alcohol or medication abuse.\n\n          7. Patients had lower respiratory tract infections or received systemic steroid in the 4\n             weeks prior to the commencement of study.\n\n          8. Unable or unwilling to comply with all protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01657487", 
            "org_study_id": "099013-F"
        }, 
        "intervention": {
            "arm_group_label": [
                "Fluticasone/salmeterol high dose", 
                "Fluticasone/Salmeterol medium dose"
            ], 
            "intervention_name": "Fluticasone/Salmeterol high dose", 
            "intervention_type": "Drug", 
            "other_name": "COPD patients treating with high dose of ICS (Fluticasone 1000ug/day) combined with Salmeterol (25ug/day)"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Salmeterol", 
                "Albuterol", 
                "Fluticasone", 
                "Fluticasone, salmeterol drug combination"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "COPD", 
            "Fluticasone/Salmeterol", 
            "high dose"
        ], 
        "lastchanged_date": "August 3, 2012", 
        "location": {
            "contact": {
                "email": "ntuhwyh61@yahoo.com.tw", 
                "last_name": "Shih-Lung Cheng, MD, PhD", 
                "phone": "888-2-89667000", 
                "phone_ext": "2816"
            }, 
            "facility": {
                "address": {
                    "city": "Taipei", 
                    "country": "Taiwan", 
                    "zip": "886"
                }, 
                "name": "Far Eastern Memorial Hospital"
            }, 
            "investigator": {
                "last_name": "Shih-Lung Cheng, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "2", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Research Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We will compare the lung function changed in COPD patients treating with different doses of Fluticasone (500 and 1000ug)", 
            "measure": "The changes of lung function parameters, including post bronchodilation forced expiratory volume in first second (FEV1) and forced vital capacity (FVC), before and after treatment.", 
            "safety_issue": "No", 
            "time_frame": "Lung function change in one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01657487"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Far Eastern Memorial Hospital", 
            "investigator_full_name": "Shih-Lung Cheng", 
            "investigator_title": "Division of Pulmonary Medicine, Department of Internal Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Annual rate of acute exacerbations\nThe number of use of rescue medication\nAnnual incidence of community-acquired pneumonia\nThe changes of Health-related quality of life assessed by questionnaire (CAT or SGRQ) before and after treatment.", 
            "measure": "Annual rate of acute exacerbations", 
            "safety_issue": "Yes", 
            "time_frame": "percentage of acute exacerbation in one year"
        }, 
        "source": "Far Eastern Memorial Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Research Ethics Review Committee", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Far Eastern Memorial Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}